Chemo‐immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Time to Retire?
Open Access
- 1 August 2019
- journal article
- editorial
- Published by Wiley in HemaSphere
- Vol. 3 (4), e278
- https://doi.org/10.1097/hs9.0000000000000278
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximabLeukemia Research, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLThe New England Journal of Medicine, 2018
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2018
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Haematologica, 2018
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceBlood, 2018
- Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsHaematologica, 2017
- Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective reviewTherapeutic Advances in Hematology, 2017
- Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task ForceAnnals of Oncology, 2016
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2015
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsThe New England Journal of Medicine, 2014